Real-World Data Enhances Efficacy Understanding of Bispecific Antibodies in MM
Initial analyses of real-world data involving bispecific antibodies for treating relapsed/refractory multiple myeloma (MM) indicated a modest reduction in efficacy compared to traditional clinical trial outcomes. This discrepancy was primarily…